Background:COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract.Some people who get COVID-19 have only mild symptoms. But for others, infection leads topneumonia, respiratory failure, and, in some cases, death. Researchers want to learn moreabout any effects that may persist after people recover from COVID-19.Objective:To learn about any long-term medical problems that people who have recovered fromCOVID-19 might have, and whether they develop an immune response to SARS-CoV-2 thatprovides protection against reinfection.Eligibility:People age 18 and older who have recovered from documented COVID-19 or were in closecontact with someone who had COVID-19 but did not get the infectionDesign:Participants will be screened over 2 visits. During visit 1, they will answer questionsabout any symptoms they are having and will be tested for SARS-CoV-2 infection which willinvolve a nasal swab sample or other FDA approved test. If the test is negative, theywill proceed to the second visit, which will include:Physical examinationMedical historyMental health interview (which may be recorded if the participant agrees)Chest x-ray (for recovered COVID-19 participants only)Blood and urine testsPregnancy test (if needed)Lung function test (for recovered COVID-19 participants only)6-minute walk test (for recovered COVID-19 participants only)Questionnaires about their general and mental healthLeukapheresis to collect white blood cells (optional).Participants will be put into 1 of 2 groups: the COVID-19 group or the close contactgroup.Participants will have study visits every 6 months for 3 years. They will repeat some ofthe screening tests. Participants in the COVID-19 group may have visits more often ifthey develop symptoms that suggest re-infection with SARS-CoV-2.

This study aims to evaluate the impact of the COVID-19 pandemic and its measures onlifestyle in Dutch children between 4 - 18 years.

This is an double-blind, randomized, placebo controlled phase III study in hospitalizedsubjects with confirmed SARS-CoV-2.

The viral Covid-19 outbreak is now considered a pandemic according to the World HealthOrganisation (WHO). A free monitoring app 'COVID-19 Symptom Tracker' has been developedto record and monitor the symptoms of the COVID-19 coronavirus infection; tracking inreal time how the disease progresses. The app also records how measures aimed atcontrolling the pandemic including self-isolation and distancing are affecting the mentalhealth and well-being of participants. The data from the study will reveal importantinformation about the symptoms and progress of COVID-19 infection in different people,and why some go on to develop more severe or fatal disease while others have only mildsymptoms do not.

The coronavirus disease 2019 (COVID-19) outbreak is now considered as a public healthemergency of international concern by the World Health Organization.In the context of the health emergency, research on the pathogen (the SARS-CoV-2coronavirus), the disease and the therapeutic care is being organized. Research projectsrequire the use of biological samples. This study aims at setting up a collection ofbiological samples intended for application projects in any discipline.The main objective of the study is to collect, process and store biological samples frompatients and caregivers infected with SARS-CoV-2 (COVID-19) at the biological ressourcescenter of the Bordeaux University Hospital.

This is an observational study of patients with COVID-19 designed to specifically addressimportant clinical questions that remain incompletely answered for coronavirus disease2019.

COVIDENCE UK is a population-based observational longitudinal study that has thefollowing objectives: 1. To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population 2. To characterise the natural history of COVID-19 in the UK population 3. To evaluate the impact of COVID-19 on the physical and mental health of the UK population 4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.

This study is an adaptive, randomized, open-label, controlled clinical trial, incollaboration with countries around the world through the World Health Organization.

The purpose of this study is to understand the impact of COVID-19 on patients with cancerthrough a survey.

Infection with the SARS-CoV-2 coronavirus (COVID-19) has recently been identified as apandemic due to the speed and global scale of its transmission. In Auvergne-Rhône-Alpesregion (AURA), the epidemic began in February 2020 and the number of infected people isstill important. Between 15 and 20% of COVID-19 patients develop an acute respiratorydistress syndrome (ARDS) leading to their hospitalization in intensive care. Theirclinical progression can be rapidly harmful with the development of severe ARDSassociated with an increased risk of death.Preliminary data on the immune response of COVID-19 patients describe the induction of amoderate inflammatory response and the occurrence of major progressive lymphopenia overtime associated with potential immunosuppression. Up to 50% of secondary infections arereported in deceased COVID-19 patients. However, no prospective study has exhaustivelydescribed the kinetics of the immune response of COVID-19 patients in intensive care.The precise description of the immune response over time in adult patients with a proveninfection with the SARS-CoV-2 virus and the study of the relation between this responseand the increased risk of organ failure (severe ARDS), death or nosocomial infection willallow us to better understand the pathophysiology of the immune response induced byCOVID-19 in order to (i) identify new therapeutic strategies targeting the host responsein patients in intensive care (ii) to develop biological markers to stratify patients forfuture clinical trials evaluating these immunoadjuvant treatments in COVID-19.